Polyclonal Antibody to V-Rel Reticuloendotheliosis Viral Oncogene Homolog A (RELA)
| Code | Size | Price |
|---|
| PAA616Mu01-20ul | 20ul | £82.00 |
Quantity:
| PAA616Mu01-100ul | 100ul | £152.00 |
Quantity:
| PAA616Mu01-200ul | 200ul | £204.00 |
Quantity:
| PAA616Mu01-1ml | 1ml | £464.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
Nuclear factor NF-kappa-B p65 subunit; NFKBP65; RELA; p65; Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells 3
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Transcription Factor P65
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:130-500<br/>Immunohistochemistry: 5-20ug/mL;1:13-50<br/>Immunocytochemistry: 5-20ug/mL;1:13-50<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant V-Rel Reticuloendotheliosis Viral Oncogene Homolog A (RELA) | RPA616Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||